How GLP-1s Work: A Plain-English Guide

GLP-1 medications (glucagon-like peptide-1 receptor agonists, if you want the mouthful) are prescription drugs that mimic a hormone your body already makes. That hormone helps regulate appetite, digestion, and blood sugar. When you take a GLP-1, your brain gets a stronger "full" signal, your stomach empties more slowly, and you naturally eat less. The clinical data is striking: participants in major trials lost an average of roughly 15% of their body weight over about 68 weeks. That's significant. It's also not the whole story.

This guide breaks down how GLP-1s actually work, which medications are on the market, what the side effects look like, what they cost, and how to figure out whether they're worth exploring. No jargon, no hype, no filler.

GLP-1 stands for glucagon-like peptide-1. It's a hormone your gut produces naturally, mostly after you eat. Its job is to tell your brain you're satisfied, signal your pancreas to release insulin, and slow down how fast food leaves your stomach. It's one of several hormones that work together to regulate hunger, fullness, and blood sugar.

Here's the thing: in most people, GLP-1 is produced in relatively small amounts and breaks down quickly. The signal it sends is real, but it's brief. GLP-1 medications are synthetic versions of this hormone, engineered to last much longer in your body than the natural version does. Instead of breaking down in minutes, these drugs stick around for days (with weekly injectables) or maintain a steady level throughout the day (with daily pills).

The result? A louder, longer-lasting "full" signal. And that changes how most people eat, without requiring willpower to override genuine hunger.

GLP-1 medications work through three main mechanisms, and understanding all three helps explain why they're as effective as they are.

They reduce appetite at the brain level. GLP-1 receptors exist in the hypothalamus, the part of your brain that regulates hunger and satiety. When a GLP-1 medication activates those receptors, it dials down hunger signals and dials up fullness signals. This isn't about suppressing cravings through sheer chemistry (like older diet pills tried to do). It's about adjusting the baseline so that you feel satisfied with less food. Most people on GLP-1s describe it as a quieting of "food noise," that constant mental chatter about what to eat next.

They slow gastric emptying. GLP-1s tell your stomach to take its time moving food into the small intestine. When food sits in your stomach longer, you feel full longer. This is also why large, rich meals often feel uncomfortable on a GLP-1. Your stomach simply isn't clearing as quickly as it used to.

They improve blood sugar regulation. GLP-1s stimulate insulin secretion when blood sugar is elevated and suppress glucagon (a hormone that raises blood sugar). This is why semaglutide was originally approved for type 2 diabetes before it became known as a weight loss drug. For people without diabetes, this mechanism contributes to more stable energy levels and fewer blood sugar spikes and crashes that can drive overeating.

These three mechanisms work together. You're less hungry, you feel full faster, and your blood sugar stays more stable. The net effect is that most people eat significantly less without feeling like they're fighting their body to do it.

The numbers from the major clinical trials are hard to ignore.

The STEP 1 trial, published in the New England Journal of Medicine, studied semaglutide (the active ingredient in Wegovy and Ozempic) at the 2.4 mg weekly dose in adults with obesity who did not have type 2 diabetes. Over 68 weeks, participants lost an average of 14.9% of their body weight, compared to 2.4% in the placebo group. That's a roughly 12.5 percentage point difference attributable to the drug. Even more notable: 86% of participants on semaglutide achieved at least 5% weight loss, and about one in three lost 20% or more.

For tirzepatide (the active ingredient in Mounjaro and Zepbound), the SURMOUNT-1 trial showed even larger results, with the highest dose producing average weight loss of approximately 22.5% over 72 weeks.

These are averages. Some people lose more. Some lose less. But the consistency of the data across thousands of participants in multiple trials is what moved the FDA to approve these medications for weight management.

One important caveat the data also makes clear: when people stop taking GLP-1 medications, the weight tends to come back. The STEP 1 trial extension data showed that participants who discontinued semaglutide regained roughly two-thirds of their lost weight within a year. This doesn't mean the drugs "don't work." It means obesity is a chronic condition, and these medications manage it rather than cure it, similar to how blood pressure medication manages hypertension.

The GLP-1 landscape has expanded rapidly. Here's what's currently FDA-approved and available for weight management as of April 2026:

Semaglutide is the most studied and most widely prescribed GLP-1 for weight management. Wegovy is the FDA-approved brand specifically for obesity. Ozempic is technically approved for type 2 diabetes, but doctors frequently prescribe it off-label for weight loss at lower doses.

The Wegovy pill, launched in January 2026, offers a non-injectable option using the same active ingredient. Clinical data from the OASIS 4 trial showed the pill achieved a mean weight loss of 13.6% at 64 weeks, slightly less than the injectable but still clinically significant.

Tirzepatide is technically a dual GIP/GLP-1 receptor agonist, meaning it targets two hormone receptors instead of one. In head-to-head comparisons, tirzepatide has shown greater weight loss than semaglutide. The SURMOUNT-5 trial confirmed tirzepatide's superiority over semaglutide for weight loss in adults without diabetes.

Foundayo is the newest addition to the GLP-1 market. Unlike the Wegovy pill (which must be taken on an empty stomach with specific water and timing requirements), Foundayo can be taken at any time of day with or without food. It's a non-peptide GLP-1, meaning it's structurally different from semaglutide and tirzepatide, which is part of why it's easier to manufacture at scale in pill form. The trade-off: it produces slightly less weight loss than the injectable options.

For years, GLP-1s were only available as weekly injections. That changed in a big way in late 2025 and early 2026 with the approval of two oral options.

The Wegovy pill (oral semaglutide 25 mg) launched in January 2026 and saw strong early adoption, with roughly 170,000 prescriptions written in its first three weeks. It delivers meaningful weight loss, though slightly less than the injectable version. The main limitation: it must be taken every morning on an empty stomach, with no more than 4 ounces of water, and you can't eat or drink anything else for at least 30 minutes.

Foundayo (orforglipron) received FDA approval in April 2026 and can be taken with or without food, at any time of day. That flexibility is a significant practical advantage, even though its overall weight loss numbers are somewhat lower than semaglutide.

For many people, the pill versus injection decision comes down to preference, convenience, and how much weight loss they need. The injectables are more potent. The pills are easier to fit into daily life. Both are legitimate medical treatments, and the best option depends on your goals, your tolerance for side effects, and what your doctor recommends.

GLP-1 medications are FDA-approved for adults who meet specific criteria:

For weight management (Wegovy, Zepbound, Foundayo): Adults with a BMI of 30 or higher (obesity), or adults with a BMI of 27 or higher (overweight) who also have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol.

For type 2 diabetes (Ozempic, Mounjaro): Adults with type 2 diabetes, where the medication helps with blood sugar control. Weight loss is a significant secondary benefit.

GLP-1s are not appropriate for everyone, and a responsible provider will screen for the following:

People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 should not take GLP-1 medications. This is a boxed warning on all GLP-1 labels.

They're also generally not recommended for people with a history of pancreatitis, severe gastrointestinal disease, or those who are pregnant or planning to become pregnant.

And candidly, if you're looking to lose 5 to 10 pounds for cosmetic reasons and don't have obesity or weight-related health conditions, a GLP-1 is probably not the right tool. These are serious medications with real side effects, designed for people managing a chronic disease. A good provider will tell you the same thing.

We're not going to sugarcoat this section. Side effects are real, and they're the main reason some people discontinue GLP-1s. But context matters, and the data paints a more nuanced picture than the headlines suggest.

Gastrointestinal issues are the most frequently reported side effects across all GLP-1 medications. In the STEP 1 trial, 74.2% of participants on semaglutide reported GI-related adverse events, compared to 47.9% in the placebo group. The most common:

Nausea is the big one. It's reported by roughly 40% of participants during the dose escalation phase (the first several weeks, when your dose is gradually increasing). For most people, it's manageable: mild queasiness, a general sense that large meals aren't appealing, reduced appetite. For a smaller percentage, it can be genuinely disruptive. The good news is that it tends to fade as your body adjusts to each new dose level.

Diarrhea and constipation are also common, sometimes alternating. Staying hydrated and eating enough fiber helps.

Vomiting affects a smaller percentage of users and is more common during dose increases.

Decreased appetite is technically a side effect, though for many people taking a GLP-1 for weight management, it's also the desired effect. The line between "side effect" and "mechanism of action" is blurry here.

Pancreatitis has been reported in a small number of cases. If you experience severe, persistent abdominal pain (especially pain that radiates to your back), contact your healthcare provider immediately.

Gallbladder problems, including gallstones, were reported at higher rates in the semaglutide group in STEP 1 (2.6%) compared to placebo (1.2%). Rapid weight loss from any cause can increase gallstone risk.

Thyroid tumors are the basis for the boxed warning on all GLP-1 labels. This risk was observed in rodent studies, and while it hasn't been confirmed in humans, the FDA requires the warning. People with a personal or family history of medullary thyroid carcinoma should not take these medications.

Here's a useful gut check: if your provider prescribes a GLP-1 without discussing potential side effects, without starting you at a low dose and titrating up gradually, or without scheduling follow-up check-ins, that's a red flag about the provider, not the medication. A good prescriber will dose you slowly, monitor your response, and adjust as needed.

GLP-1 pricing is complicated and changes frequently. Here's the landscape as of April 2026.

Wegovy (injectable semaglutide) carries a list price of $1,349 per month, though Novo Nordisk has announced a reduction to $675 per month starting in 2027. The company's self-pay program currently offers the injectable at $349 per month for the maintenance dose.

Zepbound (tirzepatide) is priced similarly, with list prices above $1,000 per month and various savings programs available for insured patients.

The GLP-1 pills have introduced more accessible pricing. Both the Wegovy pill and Foundayo start at approximately $149 per month for the lowest doses. Higher doses of Foundayo can reach up to $349 per month out of pocket. With commercial insurance and manufacturer coupons, some patients pay as little as $25 per month.

Medicare coverage for GLP-1 obesity medications is expected to begin as early as July 2026, with copays capped at approximately $50 per month for eligible patients.

Compounded versions of semaglutide (custom-mixed by compounding pharmacies, not manufactured by Novo Nordisk) have been available at significantly lower prices, sometimes $200 to $400 per month. However, the FDA has issued warnings about compounded GLP-1s, and their legal availability depends on the FDA's ongoing shortage designation for semaglutide. If the shortage designation ends, compounded versions could become unavailable.

Pricing changes frequently. We verify and update this section regularly.

Last verified: April 2026

There are three main paths to getting a GLP-1 prescription:

Your primary care doctor or an endocrinologist. This is the most traditional route. Your doctor evaluates your health history, discusses your goals, and writes a prescription if appropriate. Insurance is more likely to cover the medication when prescribed through your regular healthcare provider.

A telehealth provider. Companies like Hims, Ro, and others offer online consultations specifically for GLP-1 prescriptions. The convenience is real: you can complete a medical intake, consult with a provider, and have medication shipped to your door. The quality of these services varies significantly, though, and we've reviewed the major players in detail. (See our [Best GLP-1 Providers] guide for full reviews and Calorie Critic Scores.)

A weight management clinic or specialized program. Some people prefer a more comprehensive approach that combines medication with nutritional guidance, behavioral support, and regular monitoring. Programs like these tend to cost more but often provide a higher level of clinical oversight.

Whichever path you choose, make sure your provider is actually evaluating your health history, discussing potential side effects, and building a dosing plan that fits your situation. A quick, check-the-box online form that leads to a prescription in 15 minutes should raise questions, not confidence.

Here's something we hear a lot: "I'm on a GLP-1, so I don't need to track calories anymore." We get why people think that. The appetite suppression is powerful, and the weight comes off.

But here's the problem: GLP-1s reduce how much you eat. They don't change what you eat. And when your appetite is significantly reduced, it becomes even more important to make sure the food you do eat is giving your body what it needs, especially adequate protein to preserve muscle mass during weight loss.

This is where calorie and macro tracking becomes a complement to GLP-1 therapy, not a replacement for it. Tracking helps you see whether you're hitting your protein targets, getting enough fiber, and not under-eating to the point where you lose muscle along with fat. Several of the calorie tracking apps we've reviewed work well alongside GLP-1 use. (See our [Best Calorie Tracking Apps] roundup for our top picks.)

Whether you track formally with an app or just pay closer attention to your meals, the point is the same: a GLP-1 handles the "how much" question. You still need to answer the "what" question yourself.

Most people notice reduced appetite within the first one to two weeks of starting a GLP-1 medication. Meaningful weight loss typically becomes visible within the first month. However, because GLP-1s require gradual dose escalation (starting low and increasing over several weeks or months), the full effect isn't reached until you hit your maintenance dose, which can take 12 to 20 weeks depending on the medication and how well you tolerate the increases.

There's no one-size-fits-all answer. Clinical data shows that most people regain a significant portion of their weight after stopping a GLP-1. That said, some people use GLP-1s to reach a target weight and then transition to maintenance strategies (calorie tracking, exercise, behavioral changes) to sustain their progress. Others stay on the medication long-term. This is a conversation to have with your doctor, not a decision to make based on what worked for someone on Reddit.

Semaglutide and tirzepatide have been studied in clinical trials lasting up to two years, and real-world data now spans several years of widespread use. The long-term safety profile appears favorable, and the SELECT trial demonstrated that semaglutide actually reduces the risk of major cardiovascular events in people with obesity and existing heart disease. That said, these are relatively new medications in the context of long-term chronic use, and ongoing research continues. Your provider should be monitoring you regularly regardless.

There are no specific contraindications against moderate alcohol consumption while taking a GLP-1. However, many people on GLP-1s report that alcohol hits harder and hangovers feel worse, likely because of slowed gastric emptying. Some people also find their interest in alcohol naturally decreases, which is consistent with emerging research on GLP-1s' effects on reward pathways in the brain. Use your judgment and talk to your provider if you have concerns.

Same active ingredient (semaglutide), different doses and FDA approvals. Ozempic is approved for type 2 diabetes at doses up to 2.0 mg per week. Wegovy is approved for weight management at 2.4 mg per week. Wegovy is also available as a daily pill (oral semaglutide 25 mg). When people talk about using "Ozempic for weight loss," they're usually referring to off-label use of the diabetes medication at a lower dose than what's been studied for weight management.

Compounded medications are not FDA-approved and are not subject to the same manufacturing standards as brand-name drugs. The FDA has issued warnings about the risks of compounded semaglutide, including dosing inconsistencies and contamination concerns. Some compounding pharmacies are reputable and follow strict quality standards. Others cut corners. If you're considering a compounded GLP-1, make sure the pharmacy is licensed, the prescribing provider is evaluating your health properly, and you understand the risks. We cover this in more detail in our [Cheapest GLP-1 Options] guide.

Previous generations of weight loss medications (phentermine, fen-phen, etc.) primarily worked by stimulating the central nervous system, essentially acting as appetite suppressants that carried significant cardiovascular and addiction risks. GLP-1s work through a fundamentally different mechanism: mimicking a hormone your body already makes. The safety profile is substantially better, the weight loss is substantially greater, and the medications were developed through rigorous, large-scale clinical trials. That doesn't make them risk-free, but it makes them a different category of treatment entirely.

GLP-1 medications are the most significant advancement in obesity treatment in decades. They work through well-understood biological mechanisms, they're backed by extensive clinical data, and they produce meaningful weight loss for the majority of people who take them.

They're also not magic. They have real side effects. They're expensive (though getting less so). They require ongoing use to maintain results. And they work best when combined with good nutrition, adequate protein intake, and regular movement.

Before starting any GLP-1 medication, talk to your doctor. Not just a telehealth intake form, but a provider who will review your medical history, discuss your goals, and build a dosing plan that actually fits your situation. If the provider you're considering doesn't do that, keep looking.

We'll continue covering the GLP-1 landscape as it evolves, including in-depth reviews of the major providers, pricing updates, and practical guides for getting the most out of these medications. Subscribe to [The Weekly Weigh-In], our free newsletter, for weekly GLP-1 price alerts, recalls, and new reviews.

_{Calorie Critic is a publication of Hoot Fitness, LLC.}

_{Calorie Critic provides editorial content for informational purposes only. Nothing on this site should be construed as medical advice. GLP-1 medications are prescription drugs with real side effects and contraindications. Always consult a licensed healthcare provider before starting, stopping, or changing any medication.}